VenoStent Technology Receives Breakthrough Device Designation by FDA

Analyst Callie Cox joins Jared Blikre to help investors find opportunities in a tough market on Wed, May 18 at 2pm ET.
Designation to promote more rapid Agency and market access for VenoStent
HOUSTON, TX / ACCESSWIRE / May 17, 2022 / VenoStent, Inc., a clinical-stage tissue engineering company developing bioabsorbable perivascular wraps to improve outcomes in the 5 million vascular surgeries performed each year, announces that The Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) has granted its novel technology, the SelfWrap® Bioabsorbable Perivascular Wrap, Breakthrough Device Designation (BDD).
"We are very honored that the FDA recognizes the promise of VenoStent's SelfWrap technology to improve the quality and length of life of chronic kidney disease (CKD) patients that require hemodialysis treatments, a life-threatening condition that can be devastating for patients" says VenoStent CEO, Tim Boire. "About a year ago, we embarked on a clinical trial to assess the safety and effectiveness of our novel tissue engineering technology to help CKD patients needing dialysis, and the results of this study are highly encouraging, in terms of both safety and effectiveness. This Breakthrough Device Designation is an acknowledgement from the FDA that VenoStent's SelfWrap has established ‘a reasonable expectation of technical and clinical success' with these clinical results and is indeed a promising potential solution for CKD patients. We look forward to all of the benefits that are afforded by this designation, and the potentially profound impact that our device can have on this patient population, as well as others in the future."
For millions of patients every year, vein grafting offers the best opportunity for survival. These procedures, such as arteriovenous fistula (AVF) creation and coronary artery bypass grafting (CABG), use a vein as a replacement artery. Unfortunately, as veins are not built like arteries, these surgeries can have extremely high failure rates – some more than 50% – greatly increasing morbidity and mortality. VenoStent's device, SelfWrap, is a macroporous, bioabsorbable polymer wrap that provides scaffolding for these veins, helping them to arterialize and potentially saving thousands of lives in the process.
This BDD is an official recognition from the FDA ("the Agency") that the SelfWrap technology may provide for more effective treatment of a life-threatening or irreversibly debilitating human disease or condition, with no approved or cleared alternative available to patients. This includes the use of VenoStent's SelfWrap to improve outcomes in CKD patients that have failed or failing kidneys and are referred for vascular access creation surgery as they require hemodialysis treatments to filter out toxins in their blood that healthy kidneys would normally process. The designation brings with it a more collaborative relationship with the Agency, the potential for more adaptive clinical trial designs that can expedite FDA approval, and more rapid mechanisms for reimbursement to accelerate the availability of innovative, potentially life-saving technologies such as SelfWrap for patients.
Breakthrough Device Designation
The Breakthrough Devices Program from the FDA was created to assist companies developing promising, novel technologies treating life threatening conditions. The benefits of receiving Breakthrough Device Designation by FDA include improved Agency access with priority review, an accelerated approval process through the potential of more efficient and flexible clinical trial design, and the potential for early reimbursement access through the Transitional Pass-Through Payment and Transitional Add-On Payment programs provided by the Centers for Medicare & Medicaid Services (CMS). Individually, each one of these benefits is impactful for novel medical technologies. In aggregate, they can be transformational for a company like VenoStent, where all of these features of the program can be leveraged to the benefit of a highly vulnerable patient population.
"This is a major step towards helping chronic kidney disease patients in the United States. We are grateful to the team at FDA, our own team, and all of those who have backed us over the years," says CEO Tim Boire.
About VenoStent
VenoStent is a clinical-stage tissue engineering medical device company developing bioabsorbable smart polymer wraps to transform outcomes in vascular surgery. VenoStent's initial focus is on extending the quality and length of life of dialysis patients with a polymer wrap that goes around blood vessels to act as a tissue engineering scaffold and prevent failures. This approach can be readily adopted to improve vascular surgery outcomes for patients that suffer from peripheral artery disease (PAD) or coronary artery disease (CAD) and require arterial bypass grafting surgery (peripheral artery bypass grafting, PABG, or coronary artery bypass grafting, CABG), giving this technology the ability to treat over five million patients worldwide.
Forward-Looking Statements
Some of these statements are forward looking and the product discussed is in the investigational stage. It is not available for sale in the US nor worldwide.
Media Contact:
Jennifer Horspool
949-933-4300
Jennifer@engagementpr.com
SOURCE: VenoStent

View source version on accesswire.com:
https://www.accesswire.com/701726/VenoStent-Technology-Receives-Breakthrough-Device-Designation-by-FDA

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC). The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing mCRPC. The MAVERICK trial will be conducted as an open-label study of Abivertinib with ab
Vaccine stocks Pfizer and BioNTech rose moderately Tuesday after the Food and Drug Administration signed off on Covid boosters for children.
Birmingham catering assistant Amie Walton desperately wants “just a little” bit more time with her beloved children Harry, eight, and Mia, six
Rising COVID-19 cases are driving up the use of therapeutics, with Pfizer Inc's oral antiviral treatment Paxlovid seeing a 315% jump over the past four weeks, U.S. health officials said on Tuesday. The increase in U.S. cases and hospitalizations is starting to affect recommendations on behavior, with New York City, the nation's most populous city, advising stricter mask usage but stopping short of new mandates.
The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.
It's a natural question, since caffeine can increase your heart rate. We reached out to a cardiologist for answers.
The strong protections were only found to be effective for the previously-vaccinated
COVID-19 caught columnist Wanda Lloyd at a "moment of weakness" and sickened her. Don't let your guard down on protections, she writes.
The Omicron BA.4 subvariant is spreading across South Africa and parts of Europe, and could lead to another COVID-19 surge in the U.S. "We're definitely entering a resurgence in South Africa, and it seems to be driven entirely by BA.4 and BA.5," says Penny Moore, Ph.D., a virologist at the University of the Witwatersrand in Johannesburg, South Africa. "We're seeing crazy numbers of infections. Just within my lab, I have six people off sick." So what warning signs should people be looking for? He
The U.S. is experiencing a shortage of baby formula. The real turning point came in mid-February, after supply chain constraints were already pressuring the sector.
The rise in work-from-home jobs during the pandemic presents an opportunity to create a sea change for the 1 in 4 adults in the United States who have some type of disability.
If two years of life under the pandemic have proven anything, it's that COVID-19 is an elusive enemy with no shortage of surprises. But even as case counts have risen and fallen as the virus has taken on slightly new forms that affect its transmissibility, highly effective vaccines have helped bring hospitalization and death rates down to much lower levels than during the earliest days of the virus. This was true even for the Omicron variant, which sent the national infection rate to its highest
The federal government is again offering Americans free COVID-19 test kits through the mail, allowing for up to eight more tests to be ordered through the USPS.
A virus that shows no signs of disappearing, variants that are adept at dodging the body’s defenses and waves of infections two, maybe three times a year — this may be the future of COVID-19, some scientists now fear. The central problem is that the coronavirus has become more adept at reinfecting people. Already, those infected with the first omicron variant are reporting second infections with the newer versions of the variant — BA.2 or BA2.12.1 in the United States, or BA.4 and BA.5 in South
The experimental therapy is designed to treat a side effect of radiation therapy in cancer patients.
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.
'Made an im-POLE-sive decision to try a new workout class,' says Brie Larson as she shares next new fitness venture.
Starbucks joins a growing list of companies including Microsoft and Apple who have made similar pledges in the wake of the leaked Supreme Court opinion that would overturn Roe v. Wade.
Shares of Eli Lilly (NYSE: LLY) rose on Monday after the U.S. Food and Drug Administration (FDA) approved the pharmaceutical giant's new diabetes treatment, tirzepatide. As of 1:50 p.m. ET, Eli Lilly's stock price was up more than 3%. A phase 3 clinical trial showed tirzepatide to reduce A1C — a key measure of average blood sugar levels — better than existing treatment options.
"I knew I was done when I realized I'd never had the freedom to just be an adult."View Entire Post ›